London, UK: Ark Therapeutics Group plc (‘Ark’) announces today that it has signed an exclusive agreement with Flen Pharma, the private Belgian wound care company, giving Ark the rights to market Flaminal(R), an anti-microbial wound care gel, in the UK. Under the terms of the deal, Ark will be responsible for reimbursement and conducting all sales and marketing activities and will pay Flen Pharma a transfer price for the finished product. Ark’s existing sales force, which currently markets Kerraboot(R), a product for diabetic and venous leg ulcers, will be used to promote Flaminal(R) in the UK.
